Galapagos has dosed the first patient in the Phase II PINTA trial designed to evaluate GLPG1205 for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
The patient was dosed in a trial centre in Slovakia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Galapagos chief scientific officer Dr Piet Wigerinck said: “The first patient dosing in our PINTA Phase II trial shows the progress we are making in expanding our IPF franchise.
“We are strongly committed to the rapid development of our fully proprietary IPF portfolio to address this important unmet medical need.”
The randomised, double-blind, placebo-controlled trial aims to include up to 60 IPF patients across ten countries in Europe, North Africa, and the Middle East.
During the trial, patients will receive a 100mg once-daily oral dose of GLPG1205 or placebo for 26 weeks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPatients will have the option to remain on their local standard of care as background therapy, irrespective of whether they were previously or are currently being treated with esbriet (pirfenidone) and ofev (nintedanib).
The trial’s primary goal is to evaluate the change from baseline in Forced Vital Capacity (FVC in mL) over 26 weeks compared to placebo.
Its secondary goals comprise safety, tolerability, pharmacokinetics and pharmacodynamics, time to major events, changes in functional exercise capacity, and quality of life.
Galapagos’s GLPG1205 is a small molecule selectively antagonising GPR84, which plays a role in IPF.
IPF is a chronic, persistently developing fibrotic disorder of lungs that usually affects adults over the age of 40.
